Reply to Gan et al., to Calzetta et al., and to Poor

Affiliations

¹ South Texas Veterans Health Care System, San Antonio, Texas.
² University of Texas Health, San Antonio, Texas.
³ Division of Pulmonary and Critical Care, University of California Los Angeles, Los Angeles, California.
⁴ Midwest Chest Consultants, PC, St. Charles, Missouri.
⁵ Verona Pharma Plc, London, United Kingdom and Raleigh, North Carolina.
⁶ StatMind AB, Lund, Sweden; and.
⁷ Division of Pulmonary and Critical Care Medicine, University of Pittsburgh, Pittsburgh, Pennsylvania.

Comment

Antonio Anzueto et al. Am J Respir Crit Care Med. 2024.

. 2024 Jan 15;209(2):226-228.

doi: 10.1164/rccm.202309-1657LE.

¹ South Texas Veterans Health Care System, San Antonio, Texas.
² University of Texas Health, San Antonio, Texas.
³ Division of Pulmonary and Critical Care, University of California Los Angeles, Los Angeles, California.
⁴ Midwest Chest Consultants, PC, St. Charles, Missouri.
⁵ Verona Pharma Plc, London, United Kingdom and Raleigh, North Carolina.
⁶ StatMind AB, Lund, Sweden; and.
⁷ Division of Pulmonary and Critical Care Medicine, University of Pittsburgh, Pittsburgh, Pennsylvania.

No abstract available

Comment on

Pharmacological Interpretation of the Efficacy of Ensifentrine in Chronic Obstructive Pulmonary Disease: Insights from ENHANCE Trials.
Calzetta L, Cazzola M, Rogliani P. Calzetta L, et al. Am J Respir Crit Care Med. 2024 Jan 15;209(2):224-225. doi: 10.1164/rccm.202308-1355LE. Am J Respir Crit Care Med. 2024. PMID: 37939379 Free PMC article. No abstract available.
Still Thirsty in COPD!
Poor AD. Poor AD. Am J Respir Crit Care Med. 2024 Jan 15;209(2):225-226. doi: 10.1164/rccm.202309-1605LE. Am J Respir Crit Care Med. 2024. PMID: 37939380 Free PMC article. No abstract available.
Inhaled Dual PDE3/4 Inhibitor Ensifentrine for Chronic Obstructive Pulmonary Disease: A Potential Therapeutic Perspective.
Gan Q, Wu Y, Su X, Wang J, Zhang H, Zhang N, Wu K. Gan Q, et al. Am J Respir Crit Care Med. 2024 Jan 15;209(2):223-224. doi: 10.1164/rccm.202307-1143LE. Am J Respir Crit Care Med. 2024. PMID: 37939381 Free PMC article. No abstract available.

1. Anzueto A, Barjaktarevic IZ, Siler TM, Rheault T, Bengtsson T, Rickard K, et al. Ensifentrine, a novel phosphodiesterase 3 and 4 inhibitor for the treatment of chronic obstructive pulmonary disease: randomized, double-blind, placebo-controlled, multicenter phase III trials (the ENHANCE trials) Am J Respir Crit Care Med . 2023;208:406–416. - PMC - PubMed
1. Donohue JF, Rheault T, MacDonald-Berko M, Bengtsson T, Rickard K. Ensifentrine as a novel, inhaled treatment for patients with COPD. Int J Chron Obstruct Pulmon Dis . 2023;18:1611–1622. - PMC - PubMed
1. Boswell-Smith V, Spina D, Oxford AW, Comer MB, Seeds EA, Page CP. The pharmacology of two novel long-acting phosphodiesterase 3/4 inhibitors, RPL554 [9,10-dimethoxy-2(2,4,6-trimethylphenylimino)-3-(n-carbamoyl-2-aminoethyl)-3,4,6,7-tetrahydro-2H-pyrimido[6,1-a]isoquinolin-4-one] and RPL565 [6,7-dihydro-2-(2,6-diisopropylphenoxy)-9,10-dimethoxy-4H-pyrimido[6,1-a]isoquinolin-4-one] J Pharmacol Exp Ther . 2006;318:840–848. - PubMed
1. Rheault T, MacDonald-Berko M. Anti-inflammatory pharmacology of ensifentrine [abstract] CHEST . 2020;158:A2284.
1. Franciosi LG, Diamant Z, Banner KH, Zuiker R, Morelli N, Kamerling IM, et al. Efficacy and safety of RPL554, a dual PDE3 and PDE4 inhibitor, in healthy volunteers and in patients with asthma or chronic obstructive pulmonary disease: findings from four clinical trials. Lancet Respir Med . 2013;1:714–727. - PubMed